Antioxidant properties of cabergoline: inhibition of brain auto-oxidation and superoxide anion production of microglial cells in rats.
We evaluated the effect of cabergoline on superoxide anion production by rat microglial cells using a 2-methyl-6-(p-methoxyphenyl)-3,7-dihydroimidazo[1, 2-a]pyrazin-3-one-dependent chemiluminescence assay. Cabergoline dose-dependently inhibited superoxide anion production by microglial cells stimulated with phorbol myristate acetate or opsonized zymosan, while it had no superoxide dismutase-like activity. We also studied the effects of cabergoline and alpha-tocopherol on thiobarbituric acid reactive substances formation in homogenized brain-tissue in rats. Cabergoline was stronger than alpha-tocopherol in inhibiting auto-oxidation. While cabergoline is commonly used to treat the motor dysfunction of Parkinson's disease, it may also be effective in inhibiting oxidative stress, a possible mechanism of dopaminergic neuronal degeneration in Parkinson's disease.
Yoshida
Toshihiko
T
Department of Neurology, Gunma University School of Medicine, Showa-machi, Maebashi, Gunma 371-8511, Japan.
Tanaka
Makoto
M
Suzuki
Yoko
Y
Sohmiya
Makoto
M
Okamoto
Koichi
K
D000818:Animals; D000831:Animals, Newborn; D000975:Antioxidants / Q000494:pharmacology*; D001921:Brain / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D000077465:Cabergoline; D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D004873:Ergolines / Q000494:pharmacology*; D008297:Male; D017628:Microglia / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D010084:Oxidation-Reduction / Q000187:drug effects; D051381:Rats; D017208:Rats, Wistar; D013481:Superoxides / Q000378:metabolism*; D014810:Vitamin E / Q000494:pharmacology
D000975:Antioxidants; D004873:Ergolines; D013481:Superoxides; D014810:Vitamin E; D000077465:Cabergoline